Welcome to our dedicated page for Nuvectis Pharma news (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma stock.
Nuvectis Pharma, Inc. reports developments as a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications. Company news centers on NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, and on clinical and preclinical work in genetically or molecularly defined cancer settings.
Recurring updates include financial results, business highlights, clinical program progress, AACR and other oncology conference presentations, pharmacokinetic and pharmacodynamic findings, drug-drug interaction data, and combination-therapy research in non-small cell lung cancer and other advanced solid tumors. News also covers capital resources and financing activity tied to development operations.
Nuvectis (NASDAQ: NVCT) announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from China’s NMPA for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) patients previously untreated with complement inhibitors.
The approval is based on a head-to-head Phase 3 trial versus Soliris (eculizumab) in treatment-naive PNH patients, in which ciprocopan met all primary and secondary endpoints and showed superior efficacy and favorable safety. Haisco developed and will commercialize ciprocopan in China, while Nuvectis holds exclusive rights outside Greater China, India and certain Southeast Asian countries.
Nuvectis Pharma (NASDAQ: NVCT)/b) reported that ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, received marketing approval from China’s NMPA for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) patients previously untreated with complement inhibitors.This is the first global approval of a once-daily oral Factor B inhibitor and is based on a head-to-head Phase 3 trial versus Soliris in treatment‑naive PNH patients, where ciprocopan met all primary and secondary endpoints, showed superior hemoglobin responses and transfusion avoidance, and had no discontinuations due to adverse events. Haisco developed and controls ciprocopan in China, while Nuvectis holds exclusive rights outside Greater China, India and parts of Southeast Asia.
Nuvectis Pharma (Nasdaq: NVCT) priced an underwritten public offering of 5,000,000 common shares at $20.00 per share, targeting $100 million in gross proceeds, plus a 30-day option for 750,000 additional shares.
Proceeds will fund NXP100, NXP200, NXP900, hiring, capital spending and general corporate purposes.
Nuvectis Pharma (Nasdaq: NVCT) announced it has commenced an underwritten public offering of common stock, with all shares offered by the company and a 30-day option for underwriters to purchase up to an additional 15% of shares.
Proceeds are planned to fund NXP100, NXP200, NXP900 development, hiring, capital expenditures, public-company costs, and general corporate purposes.
Nuvectis (NASDAQ: NVCT) signed a license agreement with Haisco for exclusive ex-China rights to two clinical-stage assets: Complement Factor B inhibitor NXP100 and paradox-breaker BRAF inhibitor NXP200.
The deal adds late-stage programs in complement-mediated diseases and oncology, with patents to 2042–2043 and up to $1.461B in potential payments plus tiered royalties, subject to financing conditions.
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company developing precision oncology medicines for serious unmet medical needs, announced management participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026.
The company’s presentation, led by Chairman and CEO Ron Bentsur, is scheduled from 9:00–9:30 AM EDT in New York, NY. A live webcast will be accessible in the Investors section of the Nuvectis website.
Nuvectis Pharma (NASDAQ: NVCT) reported Q1 2026 results and clinical updates on May 5, 2026. Cash and cash equivalents were $25.1 million as of March 31, 2026, down from $31.6 million at year-end. Net loss was $6.1 million for Q1 2026. The NXP900 Phase 1b program continues to enroll in the US, with preclinical data presented at AACR showing synergy with sotorasib in NSCLC models. Management expects a preliminary Phase 1b data readout in summer 2026 and cited continued financial discipline while advancing clinical milestones.
Nuvectis Pharma (NASDAQ: NVCT) announced poster presentations for its clinical candidate NXP900 at the 2026 American Association for Cancer Research Meeting (AACR), April 17–22, 2026 in San Diego, CA.
Three abstracts will be presented April 21–22 covering synergy with KRAS inhibitors in NSCLC, resistance mechanisms in cholangiocarcinoma, and targeting MDSCs via SRC family kinase inhibition. Specific session times and titles are listed for each poster.
Nuvectis Pharma (NASDAQ: NVCT) reported 2025 results and program updates. Cash and cash equivalents were $31.6M at year-end, up from $18.5M in 2024, driven by a February 2025 public offering and ATM access. Net loss was $26.4M in 2025 versus $19.0M in 2024. Nuvectis said its Phase 1b monotherapy and osimertinib combination studies of NXP900 are enrolling, a lorlatinib combination is pending, and cash is expected to fund milestones into the second half of 2027.
Nuvectis Pharma (NASDAQ: NVCT) announced the initiation of a Phase 1b study of oral SRC/YES1 inhibitor NXP900 in combination with osimertinib (Tagrisso) for patients with EGFR-mutant non-small cell lung cancer (EGFRmut+ NSCLC) who initially responded to osimertinib and later acquired resistance.
The program follows a completed Phase 1a dose-escalation and a drug-drug interaction study; the single-agent Phase 1b study is ongoing. The company expects multiple clinical data readouts from single-agent and combination studies in 2026.